About novartis ag - NVS
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
NVS At a Glance
Novartis AG
Lichtstrasse 35
Basel, Basel-Stadt (Basle Town) 4056
| Phone | 41-61-324-11-11 | Revenue | 50.32B | |
| Industry | Pharmaceuticals: Major | Net Income | 11.94B | |
| Sector | Health Technology | 2024 Sales Growth | 10.733% | |
| Fiscal Year-end | 12 / 2025 | Employees | 75,883 | |
| View SEC Filings |
NVS Valuation
| P/E Current | 18.526 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 16.448 |
| Price to Sales Ratio | 3.936 |
| Price to Book Ratio | 4.364 |
| Price to Cash Flow Ratio | 11.239 |
| Enterprise Value to EBITDA | 10.12 |
| Enterprise Value to Sales | 4.291 |
| Total Debt to Enterprise Value | 0.145 |
NVS Efficiency
| Revenue/Employee | 663,086.594 |
| Income Per Employee | 157,360.674 |
| Receivables Turnover | 6.128 |
| Total Asset Turnover | 0.478 |
NVS Liquidity
| Current Ratio | 1.035 |
| Quick Ratio | 0.836 |
| Cash Ratio | 0.469 |
NVS Profitability
| Gross Margin | 74.074 |
| Operating Margin | 30.338 |
| Pretax Margin | 27.184 |
| Net Margin | 23.732 |
| Return on Assets | 11.341 |
| Return on Equity | 26.327 |
| Return on Total Capital | 15.857 |
| Return on Invested Capital | 17.865 |
NVS Capital Structure
| Total Debt to Total Equity | 70.967 |
| Total Debt to Total Capital | 41.509 |
| Total Debt to Total Assets | 29.278 |
| Long-Term Debt to Equity | 52.068 |
| Long-Term Debt to Total Capital | 30.455 |
Novartis Ag in the News
Drugmakers raised prices by 6.6% on average early this year
Drugmakers raised prices an average of 6.6% at the start of 2022.